Erratum

Breast Care 2016;11:20
DOI: 10.1159/000444652

In the article

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer

Bergen E, Berghoff A.S, Rudas M, Dubsy P, De Vries C, Sattlberger C, Mader R.M, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger G.G, Bartsch R.

Breast Care 2014;9:344–348 (DOI:10.1159/000368330)

Figures 1 and 2 were identical.

The correct fig. 2 is the following:

Fig. 2. Kaplan-Meier estimates for overall survival (OS). Median OS in patients receiving taxanes plus trastuzumab (group A) was 49 months (95% CI, 38.24–59.76) and 59 months (95% CI, 41.17–76.83) in patients receiving oral vinorelbine plus trastuzumab (log-rank test; $p = 0.033$).